Strongbridge Biopharma (SBBP) Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research upgraded shares of Strongbridge Biopharma (NASDAQ:SBBP) from a hold rating to a buy rating in a report released on Tuesday, Zacks.com reports. They currently have $5.00 price target on the biotechnology company’s stock.
According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
A number of other research firms have also recently weighed in on SBBP. Oppenheimer reaffirmed a buy rating on shares of Strongbridge Biopharma in a research note on Tuesday, March 19th. ValuEngine raised shares of Strongbridge Biopharma from a sell rating to a hold rating in a research note on Sunday, March 31st. TheStreet raised shares of Strongbridge Biopharma from a d- rating to a c- rating in a research note on Tuesday, February 26th. BidaskClub cut shares of Strongbridge Biopharma from a sell rating to a strong sell rating in a research note on Wednesday, March 27th. Finally, Cantor Fitzgerald set a $12.00 price target on shares of Strongbridge Biopharma and gave the stock a buy rating in a research note on Tuesday, February 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $13.29.
Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported $1.64 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $2.14. The company had revenue of $4.51 million for the quarter, compared to analysts’ expectations of $5.03 million. Strongbridge Biopharma had a net margin of 176.69% and a return on equity of 108.51%. Equities research analysts anticipate that Strongbridge Biopharma will post -1.52 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of SBBP. Stifel Financial Corp acquired a new position in shares of Strongbridge Biopharma during the 4th quarter worth $73,000. Citadel Advisors LLC acquired a new stake in Strongbridge Biopharma in the 3rd quarter valued at about $157,000. Tibra Equities Europe Ltd acquired a new stake in Strongbridge Biopharma in the 1st quarter valued at about $324,000. Marshall Wace LLP acquired a new stake in Strongbridge Biopharma in the 3rd quarter valued at about $1,290,000. Finally, D. E. Shaw & Co. Inc. grew its stake in Strongbridge Biopharma by 89.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 355,874 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 168,243 shares during the last quarter. 49.10% of the stock is currently owned by institutional investors and hedge funds.
About Strongbridge Biopharma
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
See Also: What is Cost of Goods Sold (COGS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.